Core Viewpoint - Fosun Pharma (01652) announced the resignation of KPMG as its auditor due to a failure to reach an agreement on the proposed audit fees for the fiscal year ending December 31, 2025 [1] Group 1 - The resignation of KPMG will be effective from December 24, 2025 [1] - Zhongzheng Tianheng Accounting Firm has been appointed as the new auditor to fill the vacancy left by KPMG, effective from December 24, 2025 [1] - The term of the new auditor will last until the conclusion of the next annual general meeting of the company [1]

Group 1 - The company, Fosen Pharmaceutical (01652), announced that it has terminated its auditor, KPMG, due to a failure to reach an agreement on the proposed audit fees for the fiscal year ending December 31, 2025 [1] - Zhongzheng Tianheng Accounting Firm has been appointed as the new auditor to fill the vacancy left by KPMG, effective from December 24, 2025, until the conclusion of the next annual general meeting [1]

Group 1 - The core point of the article is that Fosen Pharmaceutical (01652.HK) announced the resignation of KPMG as the company's auditor due to a failure to reach an agreement on the proposed audit fees for the financial year ending December 31, 2025 [1] - The board has appointed Zhongzheng Tianheng as the new auditor to fill the vacancy left by KPMG, effective from December 24, 2025, until the conclusion of the next annual general meeting [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）宣佈，由於董事會與畢馬威會計師事務所（「畢 馬威」）未能就本集團截至2025年12月31日止財政年度綜合財務報表的建議審核費 用達成共識，故畢馬威已辭任本公司核數師，自2025年12月24日起生效。 本公司根據開曼群島法律註冊成立，據董事會所知，開曼群島法律並無規定退任 核數師確認是否有任何情況因其退任而致使其認為應提請本公司股東（「股東」）垂 注。因此，畢馬威並無出具有關確認函。董事會及本公司審核委員會（「審核委員 會」）確認，除上文披露者外，畢馬威與本公司之間概無意見分歧，亦無其他有關 上述核數師辭任的事宜或狀況須提請股東垂注。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 核數師 ...

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its "Nicardipine Hydrochloride Injection," which is intended for emergency treatment of abnormal hypertension during surgery and hypertensive emergencies [1][2] Group 1: Product Approval and Market Potential - The approval of Nicardipine Hydrochloride Injection is significant as it is recommended in various hypertension management guidelines, including the 2020 International Society of Hypertension's Global Hypertension Practice Guidelines and the Chinese Hypertension Emergency Diagnosis and Treatment Guidelines [1][2] - The sales scale of Nicardipine Hydrochloride Injection in Chinese public medical institutions is projected to exceed 600 million RMB in 2024, with a double-digit growth rate from 2022 to 2024, showing year-on-year increases of 35.71%, 16.09%, and 14.14% respectively [1] Group 2: Product Advantages and Market Position - Nicardipine Hydrochloride Injection is characterized by rapid onset, stable blood pressure reduction, and comprehensive organ protection, with non-toxic metabolites and enhanced vascular selectivity, making it safer for patients [2] - Fosen Pharmaceutical offers a complete range of specifications for Nicardipine Hydrochloride Injection, including 5ml:5mg, 2ml:2mg, and 10ml:10mg, catering to diverse patient treatment needs and achieving high market recognition [2] - The quality and efficacy of Fosen Pharmaceutical's Nicardipine Hydrochloride Injection are consistent with reference formulations, allowing it to serve as a substitute for the original drug in clinical settings [2]

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its product, Nicardipine Hydrochloride Injection, which is intended for the emergency management of abnormal hypertension during surgery and hypertensive emergencies [1][2] Group 1: Product Approval and Market Potential - The consistency evaluation application for Nicardipine Hydrochloride Injection has been approved, indicating its readiness for clinical use [1] - The sales scale of Nicardipine Hydrochloride Injection in Chinese public medical institutions is projected to exceed 600 million RMB in 2024, with a double-digit growth rate expected from 2022 to 2024, showing year-on-year increases of 35.71%, 16.09%, and 14.14% respectively [1] - The product is recognized as a first-line treatment in various hypertension management guidelines, including the 2020 International Society of Hypertension's Global Hypertension Practice Guidelines and the Chinese Hypertension Emergency Diagnosis and Treatment Guidelines [1] Group 2: Product Advantages and Specifications - Nicardipine Hydrochloride Injection is noted for its rapid onset, stable blood pressure reduction, and comprehensive organ protection, with a non-toxic metabolic profile and enhanced vascular selectivity [2] - The company has been selling the 5ml:5mg specification in the domestic market for several years, achieving high market recognition, and has also received approval for additional specifications of 2ml:2mg and 10ml:10mg [2] - Fosen Pharmaceutical is one of the few companies in China to offer a complete range of specifications for Nicardipine Hydrochloride Injection, catering to diverse patient treatment needs [2]

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its "Nicardipine Hydrochloride Injection," which is intended for the emergency management of abnormal hypertension during surgery and hypertensive emergencies [1][2] Group 1: Product Approval and Market Potential - The consistency evaluation application for Nicardipine Hydrochloride Injection has been approved, indicating its readiness for clinical use in critical situations [1] - The sales scale of Nicardipine Hydrochloride Injection in Chinese public medical institutions is expected to exceed 600 million RMB in 2024, with a double-digit growth rate projected from 2022 to 2024, showing year-on-year increases of 35.71%, 16.09%, and 14.14% respectively [1] - The product is recognized as a first-line treatment in various hypertension management guidelines, including the 2020 International Society of Hypertension's Global Hypertension Practice Guidelines and the Chinese Hypertension Emergency Diagnosis and Treatment Guidelines [1] Group 2: Product Features and Competitive Advantage - Nicardipine Hydrochloride Injection is characterized by rapid onset, stable blood pressure reduction, and comprehensive organ protection, with non-toxic metabolites and enhanced safety [2] - The company offers a complete range of specifications for Nicardipine Hydrochloride Injection, including 5ml:5mg, 2ml:2mg, and 10ml:10mg, catering to diverse patient needs [2] - The quality and efficacy of Fosen Pharmaceutical's Nicardipine Hydrochloride Injection are consistent with reference formulations, allowing it to serve as a substitute for the original drug in clinical settings [2]

（於開曼群島註冊成立的有限公司） （股份代號：1652） 自願公告 「鹽酸尼卡地平注射液」一致性評價申請獲批上市 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 – 2 – 根據米內網資料顯示，2024年鹽酸尼卡地平注射液在中國公立醫療機構終端銷售 規模超過6億元人民幣，近年中國三大終端六大市場銷售規模快速擴容，2022年– 2024年保持雙位數增速，分別同比增長35.71 %、16.09 %、14.14 %。 福森藥業有限公司 主席兼執行董事 曹智銘先生 香港，2025年12月12日 於本公告日期，本公司董事會包括執行董事曹智銘先生（ 主席 ）、侯太生先生、遲 永勝先生及孟慶芬女士；及獨立非執行董事李國棟先生、杜潔華博士及余浩銘先 生。 福森藥業有限公司（「本公司」，連同其附屬公 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | 本月底法定/註冊股本總額： HKD 20,000,0 ...

Group 1 - Fosen Pharmaceutical (01652.HK) experienced a significant increase in stock price, rising over 7% [1] - As of the latest update, the stock price reached 0.88 HKD, reflecting a gain of 7.32% [1] - The trading volume amounted to 1.264 million HKD [1]